Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharmaceuticals, Inc. - Class A Common Stock (NQ: RETA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
REATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA
From Kahn Swick & Foti, LLC
Via Business Wire
Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review
Many leaders flashed buy signals as the indexes rebounded from support. 
Via Investor's Business Daily
Why Reata Pharmaceuticals Stock Skyrocketed This Week
A major regulatory approval lit a fire underneath Reata's shares this week. 
Via The Motley Fool
Why is OncoSec Medical (ONCS) Stock Up 91% Today?
OncoSec Medical (ONCS) stock is rising higher with heavy trading on Wednesday after the company withdrew a public stock offering. 
Via InvestorPlace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring, But Not Yet Talking About
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. Retail traders have countless methods at their disposal to uncover new information. For some, this... 
Via Benzinga
Why Is Reata Pharmaceuticals Stock Trading Higher Today?
Reata Pharmaceuticals (NASDAQ: RETA) shares are trading higher on Wednesday after the company announced the FDA approved SKYCLARYS for the treatment of Friedreich's ataxia. 
Via Benzinga
Nasdaq Down 75 Points; B&G Foods Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 75 points on Wednesday. The Dow traded down 0.19% to 32,596.21 while the NASDAQ fell 0.66% to 11,379. The... 
Via Benzinga
Dow Looking To Rebound After Rocky February
The Dow Jones Industrial Average is up 81 points this afternoon, while the S&P 500 Index and Nasdaq Composite are lower, with stocks kicking off a new month after a February decline. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Reata Pharma Shares Are Skyrocketing Today
Via Benzinga
Reata Pharma Stock Halted After Winning 'Coin-Flip' FDA Approval
The FDA approved Reata's Friedreich's ataxia treatment, Skyclarys. 
Via Investor's Business Daily
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Dow Edges Higher; ISM Manufacturing PMI Rises In February
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 30 points on Wednesday. The Dow traded up 0.12% to 32,695.97 while the NASDAQ fell 0.23% to 11,429.16. The S&P 500... 
Via Benzinga
FDA Grants Approval of Reata Pharmaceuticals’ (NASDAQ: RETA) SKYCLARYS Drug, Making the First and Only Drug for Friedreich’s Ataxia
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization 
Via Spotlight Growth
Exposures Product Safety
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
US Stocks Edge Lower; Dollar Tree Profit Beats Views
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 30 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.09% to 32,626.82 while... 
Via Benzinga
Reata Pharmaceuticals Gets Price Target Bumps By Analysts Following FDA Approval Of Skyclarys
Reata Pharmaceuticals Inc (NASDAQ: RETA) reported the FDA approval of SKYCLARYS for patients with Friedreich's ataxia. With this approval, the FDA granted a rare pediatric disease priority review... 
Via Benzinga
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
Markets are trying to rise, and these companies are helping out. 
Via The Motley Fool
Why Is Novavax (NVAX) Stock Down 26% Today?
Novavax (NVAX) stock is dropping on Wednesday after the vaccine company warned investors about the state of its business. 
Via InvestorPlace
Why Is OKYO Pharma (OKYO) Stock Down 31% Today?
OKYO Pharma (OKYO) stock is taking a beating on Wednesday despite recent progress toward a Phase 2 clinical trial for dry eye treatment. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Why Is Reata Pharmaceuticals (RETA) Stock Up 175% Today?
Reata Pharmaceuticals (RETA) stock is rocketing higher on Wednesday following approval from the FDA for one of its drugs. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals Unusual Options Activity For February 27
A whale with a lot of money to spend has taken a noticeably bearish stance on Reata Pharmaceuticals. Looking at options history for Reata Pharmaceuticals (NASDAQ:RETA) we detected 22 strange trades. 
Via Benzinga
Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test. 
Via Benzinga
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit
The FDA is set to review the company's neurological drug by Tuesday. 
Via Investor's Business Daily
Why Reata Pharmaceuticals Shares Are Falling Monday?
According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.